FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology. The invention is implemented by leukocyte recovery from heparin stabilised peripheral blood by mixing with polyglucin for 30 minutes, cultivation in a RPMI or DMEM medium with 2-10 % patient's serum (or AB blood serum). Then, G-CSF in end concentration 500-5000 IU/ml is added to the medium, and leukocytes are cultivated for 48-72 h in a CO2-incubator environment.
EFFECT: use of the method allows simplifying blood lymphocyte recovery and using produced activated leukocytes for treating oncologic patients and preventing suppurative septic complications following extensive operations and chemoradiotherapy.
2 cl, 3 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CYTOGENETIC ACTIVATION OF HUMAN LYMPHOCYTES | 2015 |
|
RU2603079C2 |
| METHOD FOR PREPARING ACTIVATED MONONUCLEAR LEUKOCYTES | 2009 |
|
RU2402338C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| METHOD OF PRODUCING CYTOTOXIC LYMPHOCYTES USING IFN-γ AND TNF-α FOR ADOPTIVE IMMUNOTHERAPY | 2023 |
|
RU2822876C2 |
| METHOD OF OBTAINING DEPOSITED LYMPHOKINE-ACTIVATED KILLER CELLS | 2009 |
|
RU2400238C1 |
| METHOD FOR CANCER ADOPTIVE IMMUNOTHERAPY | 2016 |
|
RU2613884C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| AUTOLOGOUS VACCINE FOR ONCOTHERAPY AND METHOD FOR PREPARING THEREOF | 2008 |
|
RU2392946C2 |
| METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
| METHOD FOR ACTIVATION OF CYTOTOXIC LYMPHOCYTES | 2019 |
|
RU2751837C2 |
